VAXIN LAUNCHES JOINT VENTURE WITH ANC BIO IN KOREA
Plexxikon Treats Initial Patient With First-in-Class Drug in Phase 1 Trial
Biovail Provides Update on Pimavanserin Collaborative Development Program
KIMBERLY-CLARK ANNOUNCES DEFINITIVE AGREEMENT TO ACQUIRE I-FLOW CORPORATION
To keep up to date with news from this category use our
Retigabine Regulatory Update
Monday 02 November 2009, London UK and California US -- GlaxoSmithKline (GSK) and Valeant Pharmaceuticals International (VRX) announced today that, on 30 October, they filed a New Drug Application with the US Food and...
Lundbeck starts clinical phase IIa with Lu AA24493 (cEPO) in Friedreich's ataxia in a study also assessing efficacy via biomarkers
November 02, 2009 -- H. Lundbeck A/S strengthens its pipeline of pharmaceuticals in clinical development by initiating phase IIa clinical studies with the innovative project Lu AA24493 in order to evaluate safety and...
Novel agent for treatment of Parkinson's disease - Lu 02-750 - enters Lundbeck's development pipeline
October 30, 2009 -- H. Lundbeck A/S strengthens its pipeline of pharmaceuticals in clinical development by initiating phase I clinical studies with Lu 02-750 in order to investigate safety, tolerability and the...
Canadian authorities grant product approval for Intercell's Vaccine to prevent Japanese Encephalitis
Vienna, Austria, October 30, 2009 - Intercell AG (VSE: ICLL) today announced that the Health Canada granted product approval for IXIARO
MAP Pharmaceuticals Completes Interim Safety Review of LEVADEX(TM) Open-Label Safety Extension in More Than 400 Patients
MOUNTAIN VIEW, Calif., October 29, 2009 -- MAP Pharmaceuticals, Inc. (Nasdaq: MAPP) today announced that it has completed a planned interim safety review of the open-label, long-term safety extension of the company's...
Pain Therapeutics Reports Third Quarter 2009 Results
SAN MATEO, Calif., Oct. 29, 2009 -- Pain Therapeutics, Inc. (Nasdaq:PTIE), a biopharmaceutical company, today reported financial results for the quarter ended September 30, 2009.
ELEKTA'S RADIOSURGERY SOLUTIONS ON CENTER STAGE AT 2009 CONGRESS OF NEUROLOGICAL SURGEONS ANNUAL MEETING EXTEND RECEIVES FDA 510(K) CLEARANCE
Stockholm, Sweden, October 23, 2009 -- At the 2009 Congress of Neurological Surgeons (CNS) Annual Meeting, October 24-28 in New Orleans, Louisiana, Elekta will demonstrate how its line of stereotactic solutions expand...
Exelixis and Bristol-Myers Squibb Report New Phase 2 Data for XL184 in Patients With the Most Common and Aggressive Form of Brain Cancer
SOUTH SAN FRANCISCO, Calif. & NEW YORK-- October 23, 2009-- Exelixis, Inc. (Nasdaq:EXEL) and Bristol-Myers Squibb Company (NYSE:BMY) today reported updated phase 2 clinical data which show that XL184 demonstrated...
Icagen Describes Progress in Its Collaboration With Pfizer to Identify Selective Sodium Channel Inhibitors
RESEARCH TRIANGLE PARK, N.C., October 19, 2009 -- Icagen, Inc. (Nasdaq:ICGN) today announced that data related to its collaboration with Pfizer focused on certain sodium channels for the treatment of pain and related...
VAXIN LAUNCHES JOINT VENTURE WITH ANC BIO IN KOREA
Birmingham, Alabama - October 14, 2009 - Vaxin Inc., an emerging vaccine company today announced that it has entered into a joint venture with South Korean biomedical company, AnC Bio Group to develop, manufacture and...
Suven's Clinical Candidate SUVN-502 For Alzheimer's disease Secures product patents in several Key markets in the world
HYDERABAD, INDIA (Oct' 14, 2009): Suven Life Sciences Ltd (Suven) announces today that their clinical candidate SUVN-502 for Alzheimer's Disease secured several product patents granted at all the key market countries;...
HyperBranch Receives CE Mark for NuSeal 30 Hernia Mesh Fixation Sealant
Durham, NC (October 13, 2009) - HyperBranch Medical Technology, Inc. announced today that it has received a CE Mark for its NuSeal 30 hernia mesh fixation sealant product. NuSeal 30 is used in hernia procedures to...
GlaxoSmithKline and Prosensa form alliance to fight Duchenne Muscular Dystrophy
Issued: 13 October 2009, London, UK & Leiden, The Netherlands - GlaxoSmithKline (GSK) and Prosensa, the Dutch based biopharmaceutical company focusing on RNA modulating therapeutics, today announced that they have...
KIMBERLY-CLARK ANNOUNCES DEFINITIVE AGREEMENT TO ACQUIRE I-FLOW CORPORATION
DALLAS and LAKE FOREST, Calif., October 9, 2009 - Kimberly-Clark Corporation (NYSE: KMB) and I-Flow Corporation (NASDAQ: IFLO), a leading healthcare company that develops and markets technically advanced, low-cost drug...
The Institute of Cancer Research and The Royal Marsden Honoured with Oncology Award
October 09, 2009 -- A programme to improve cancer pain management has won The Institute of Cancer Research (ICR) in collaboration with The Royal Marsden NHS Foundation Trust recognition for the Best Professional...
Acorda Therapeutics Announces Posting of Briefing Documents for October 14 FDA Advisory Committee Meeting on Fampridine-SR
HAWTHORNE, N.Y.--Oct. 9, 2009-- Acorda Therapeutics, Inc. (Nasdaq: ACOR) today announced that the U.S. Food and Drug Administration (FDA) has posted on its website briefing documents for the Peripheral and Central...
Plexxikon Treats Initial Patient With First-in-Class Drug in Phase 1 Trial
BERKELEY, Calif. - October 8, 2009 -- Plexxikon Inc. today announced that dosing of cancer patients with PLX3397 has started in a Phase 1 clinical trial. PLX3397 is a novel, oral investigational drug for treating...
Bayer Schering Pharma collaborates with AC Immune in the field of Alzheimer
Berlin, Germany, October 8, 2009 - Bayer Schering Pharma AG, Germany, will provide its development candidate florbetaben, a so called PET (positron emission tomography) tracer, to the Swiss-based biopharmaceutical...
NeuroSearch initiates a clinical study with ACR325 for the treatment of dyskinesias (involuntary movements) in Parkinson's disease
Copenhagen, 8 October 2009 - NeuroSearch (NEUR) today announced the initiation of a clinical Phase Ib study of ACR325, a dopaminergic stabiliser for the treatment of dyskinesias in Parkinson's disease. Dyskinesias are...
Bayer Schering Pharma collaborates with AC Immune in the field of Alzheimer
Berlin, Germany, October 8, 2009 - Bayer Schering Pharma AG, Germany, will provide its development candidate florbetaben, a so called PET (positron emission tomography) tracer, to the Swiss-based biopharmaceutical...
Canadian patent strengthens IP for Allon's 2nd technology platform
VANCOUVER -- October 8, 2009 - Allon Therapeutics Inc. (TSX: NPC), announced today that the intellectual property underlying its activity-dependent neurotrophic factor (ADNF) technology platform has been strengthened by...
Canadian patent strengthens IP for Allon's 2nd technology platform
VANCOUVER -- October 8, 2009 - Allon Therapeutics Inc. (TSX: NPC), announced today that the intellectual property underlying its activity-dependent neurotrophic factor (ADNF) technology platform has been strengthened by...
Nutra Pharma Announces Nyloxin Rx, a Prescription Analgesic for the Treatment of Severe (Stage 3) Chronic Pain
October 07, 2009 -- Nutra Pharma Corp., a biotechnology company that is developing treatments for Adrenomyeloneuropathy (AMN), HIV and Multiple Sclerosis (MS), has announced today its intent to launch a prescription...
IDEA updates on Diractin
Munich, Germany - October 7, 2009. IDEA AG today announced the results and implications of two phase III clinical studies comparing the targeted analgesic Diractin
Biovail Provides Update on Pimavanserin Collaborative Development Program
TORONTO--Oct. 6, 2009-- Biovail Corporation (NYSE/TSX: BVF) today provided an update on its Phase III program with pimavanserin for Parkinson's disease psychosis (PDP), which is being pursued in collaboration with...
Depomed, Inc. Announces Positive Top-Line Results from Phase 3 Clinical Trial of DM-1796 in Postherpetic Neuralgia
MENLO PARK, Calif.--Oct. 5, 2009-- Depomed, Inc. (NASDAQ:DEPO) today announced top-line results from a Phase 3 clinical trial demonstrating DM-1796 (also referred to as gabapentin ER) achieved a statistically...
Positive phase II results for GSK1838262 (XP13512) reported for subjects with post-herpetic neuralgia and a history of inadequate response to gabapentin
Monday 5 October 2009, Research Triangle Park, NC & Santa Clara, CA -- GlaxoSmithKline (NYSE: GSK) and XenoPort, Inc. (Nasdaq: XNPT) today announced top-line results from a Phase II clinical trial evaluating...
Positive Phase II Results for GSK1838262 (XP13512) Reported for Subjects with Post-Herpetic Neuralgia and a History of Inadequate Response to Gabapentin
RESEARCH TRIANGLE PARK, N.C. & SANTA CLARA, Calif.---Oct. 5, 2009-- GlaxoSmithKline (NYSE:GSK) and XenoPort, Inc. (Nasdaq:XNPT) today announced top-line results from a Phase II clinical trial evaluating...
Santhera Reports Closing of Juvantia Acquisition and Final Upfront Payment from Partner Biovail
Liestal, Switzerland, October 5, 2009 - Santhera Pharmaceuticals (SIX: SANN), a Swiss specialty pharmaceutical company focused on orphan neuromuscular diseases, announced today the final closing of the acquisition of Oy...
GENFIT: RESULTS FOR FIRST HALF OF 2009
Lille (France), Cambridge (Massachusetts, United States), October 2, 2009 - GENFIT (Alternext: ALGFT; ISIN: FR0004163111), a biopharmaceutical company at the forefront of drug discovery and development, focusing on the...
Mylan Receives FDA Approval for Generic Version of Parkinson's Treatment Sinemet
PITTSBURGH, September 30, 2009 -- Mylan Inc. (NASDAQ: MYL) today announced that its subsidiary Mylan Pharmaceuticals Inc. has received approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New...
Pfizer and Eisai Continue Aricept Collaboration
NEW YORK-September 25, 2009---Pfizer Inc (NYSE: PFE) today announced that its agreement with Eisai to provide Aricept to patients suffering from Alzheimer's disease will continue without interruption. Under this...
FDA Advisory Committee Hears Presentations and Public Comment on EXALGO Extended-Release Tablets
CAMBRIDGE, Mass. & VANCOUVER, Sep 23, 2009 -- CombinatoRx, Incorporated (NASDAQ: CRXX) and Neuromed Pharmaceuticals, Inc., a privately-held biopharmaceutical company, today announced that the U.S. Food and Drug...
CombinatoRx Stock Trading Halted Today; FDA Advisory Committees Meet to Discuss Exalgo
CAMBRIDGE, Mass. & VANCOUVER--Sep. 23, 2009-- CombinatoRx, Incorporated (NASDAQ: CRXX) announced that NASDAQ has halted trading in the Company's common stock today. The U.S. Food and Drug Administration's (FDA)...
CombinatoRx and Neuromed Announce Posting of Briefing Documents for FDA Advisory Committee
CAMBRIDGE, Mass. and VANCOUVER, B.C.--Sep. 22, 2009-- CombinatoRx, Incorporated (NASDAQ: CRXX) and Neuromed Pharmaceuticals, Inc., a privately-held biopharmaceutical company, today announced that the U.S. Food and Drug...
Icagen Announces Extension of Pfizer Collaboration
RESEARCH TRIANGLE PARK, N.C., September 21, 2009 -- Icagen, Inc. (Nasdaq:ICGN) today announced a one year extension to a prior worldwide collaboration and licensing agreement with Pfizer aimed at discovering, developing...
FDA Accepts for Filing Mylan's ANDA for Generic Copaxone
PITTSBURGH, September 14, 2009 -- Mylan Inc. (NASDAQ: MYL) today announced that the U.S. Food and Drug Administration (FDA) has accepted for filing Mylan Pharmaceutical Inc.'s abbreviated new drug application (ANDA) for...
MAP Pharmaceuticals' Analysis of Positive Phase 3 LEVADEX(TM) Data To Be Presented in Late-Breaking Session at 14th Congress of the International Headache Society
MOUNTAIN VIEW, Calif., September 10, 2009 -- MAP Pharmaceuticals, Inc. (Nasdaq: MAPP) announced today that it will present analysis of data from the efficacy portion of the first Phase 3 trial of its novel LEVADEX(TM)...
PTC THERAPEUTICS ANNOUNCES DRUG DISCOVERY COLLABORATION WITH ROCHE
SOUTH PLAINFIELD, N.J., September 2, 2009 - PTC Therapeutics, Inc. (PTC) today announced an exclusive research collaboration and licensing agreement with Roche for the development of orally bioavailable small molecules...
© Copyright 1995-2009 Pharmalicensing, a division of UTEK Europe Ltd 
All rights reserved. Terms and Conditions | Contact us
